With the new product launch of a practice exam for the Medical Technologist (MT) exam, AMT now offers practice tests for its respected laboratory certifications including Medical Technologists (MTs), Medical Laboratory Technicians (MLTs) and Phlebotomists.

“With a new practice test for those preparing to take the certification exam for medical technologist through AMT, candidates have an important tool to take them a step closer to becoming certified members of the clinical laboratory community,” said Christopher Damon, JD, executive director of AMT.

AMT is recognized for 1) its robust eligibility requirements for laboratory certification, which includes a BS requirement for MT certification and 50 successful venipunctures for phlebotomy technicians; 2) its rigorous exam process; and 3) its flexible and affordable requirements for maintenance of certification with a low annual fee that includes membership and discounted CE.

Medlab will take place from 6-9 February 2017 at the Dubai International Convention & Exhibition Centre, Dubai, UAE. The AMT booth number is Z5.C41.

American Medical Technologists (AMT) is an internationally recognized certification agency for allied health professionals, including Medical Technologists (MTs), Medical Laboratory Technicians (MLTs), Medical Laboratory Assistants, and Phlebotomists. A mission driven non-profit for more than 75 years, AMT is also a membership association, providing conti­nuing education and other services to more than 13,000 MT and MLT members.

To help advance the allied health sector in the Middle East and North Africa region (MENA), AMT is represented by Medogy, a leader in enhancing healthcare and life sciences in MENA region.

Visit us at www.americanmedtech.org

Charles de Rohan, CEO from Binding Site commented “The results we‘ve seen have been fantastic with labs reporting an average of 40 per cent decrease in the time it takes for them to run Optilite, compared with other market leading protein systems.”

Optilite is designed for workflow optimisation and stores up to 36 different reagents on board at any one time. As well as the Freelite®, Hevylite® and subclass assays, Optilite offers a comprehensive menu for special protein analysis.

Continuous loading of samples, reagents and consumables plus automatic re-dilution to end result, enables labs to maximise test throughput whilst minimising hands on time. With multilingual touch-screen technology and automatic barcode recognition, Optilite has been designed with the user in mind and at just 94 x 70 x 62cm, is one of the smallest systems on the market. It is so easy to use that minimum training is required and any level of staff can be confident with the results.

Optilite has robust antigen excess protection, with three different detection methods, that can be tailored to individual assays, thereby ensuring accurate and reliable results.

De Rohan added: “We wanted to bring simplicity to complex analytical processes. The result is Optilite, the latest innovation in special protein testing, which offers laboratories reliable results without compromising speed and efficiency.”

 

Ends

 

The Binding Site

With its origins in the Medical School of Birmingham University, Binding Site is now one of the largest independent providers for in vitro diagnostic tests and equipment in the UK. Exporting over 90% of its products overseas, it is the world leader in special protein testing.

Today it employs more than 700 people and has offices in all major markets worldwide.

Freelite®

Freelite is a polyclonal free light chain assay developed by the Binding Site to detect and monitor B-cell dyscrasias, including Multiple Myeloma (MM).

MM is characterised by the excess production of immunoglobulin free light chains (kappa or lambda) that are polymorphic in nature, Freelite  polyclonal antisera is able to recognise these variations ensuring sensitive and specific detection.

Freelite is: 

• A highly sensitive and specific latex-based test that evaluates both free kappa and free lambda levels.
• A quantitative, rapid and automated assay measuring only free kappa and free lambda light chains.
• The only assay recommended by both national and international guidelines including the International Myeloma Working Group Guidelines for diagnosis and monitoring of MM and related disorders.
• FDA cleared and CE marked as well as registered with a wide range of regulatory authorities.

Singapore, 16 December 2017 – AITbiotech Pte Ltd, the Singapore based genomic service and Molecular Diagnostics (MDx) company, is pleased to announce its first participation in Medlab, the world’s largest laboratory exhibition and congress in the middle east, to be held from Feb 6-9, 2017 at the Dubai International Convention & Exhibition Centre, UAE.

The Medlab exhibition is an ideal platform for industry players to meet and develop business contacts with the medical and scientific community in the Middle East and from many other countries around the world. With over 600 exhibitors from over 30 countries, the Medlab exhibition aim to attract 30, 000 visitors from across the world in 2017.  AITbiotech will use this opportunity to exhibit its comprehensive range of abTES™ Molecular Diagnostics (MDx) assays, including the newly launched Zika assays and the multiplex respiratory panel.

 

According to Alex Thian, CEO of AITbiotech; “We are exciting to be part of this premier exhibition. After many years of development of our assays and focusing in the Asia Pacific market, we are finally are able to expand to more markets. We believe that Middle East will be the best market for us to expand into, primarily due to the relevance of our abTES™ assay offerings to the needs of the Middle East Market. We are looking for local partners to work with us collaboratively to introduce our abTES™ MDx assays to the Middle East market.”

About AITbiotech
AITbiotech is a leading Genomic Service and Molecular Diagnostics (MDx) company based in Singapore. Founded by Alex Thian in 2008, it has a core molecular services and R & D laboratory in Singapore managed by a team of experienced biotechnologists. It provides a complete suite of genomic services including capillary sequencing, next-generation sequencing services, bioinformatics services and customized molecular services to the research, healthcare and biomedical industries in Singapore and Asia. AITbiotech is also an ISO 13485 certified company which manufactures and distributes its own line of real-time PCR pathogen detection assays branded as abTES™ in the Asian and European markets. For more information, please visit our website: www.aitbiotech.com.

AITbiotech is at Booth No: Z4.C46. For information about AITbiotech, please visit: www.aitbiotech.com

Hui Mian Tham                                                             

MDx Product Manager

AITbiotech Pte Ltd

+65 6777 6822

huimian@aitbiotech.com 

www.aitbiotech.com

Calvin Sum

Product & Application Manager

AITbiotech Pte Ltd

+65 6778 6822

calvin@aitbiotech.com 

www.aitbiotech.com